Theravance Biopharma (TBPH) Misses Q4 EPS by 7c

Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($0.15), $0.07 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $15.4 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Amtech Systems closes $60 million public stock offering
• C3.ai (AI) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY27 Revenue Guidance